The phosphoinositide 3-kinase pathway and therapy resistance in cancer

F1000Prime Reports

Volumn 7, Issue , 2015, Pages

  Brown, Kristin K ^a   Toker, Alex ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE MUTATION; HORMONAL THERAPY; HUMAN; MOLECULARLY TARGETED THERAPY; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84922349096     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P7-13     Document Type: Article

References (66)

1. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
2. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014, 511:543-50.
3. Kandoth C, Schultz N, Cherniack A.D., Akbani R., Liu Y, Shen H, Robertson A.G., Pashtan I., Shen R, Benz CC, Yau C, Laird P.W., Ding L., Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA: Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73.
4. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-7.
5. Hollander MC, Blumenthal GM, Dennis PA: PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nature reviews. Cancer 2011, 11:289-301.
6. Carpten JD, Faber AL, Horn C, Donoho G.P., Briggs SL, Robbins CM, Hostetter G, Boguslawski S., Moses TY, Savage S, Uhlik M, Lin A., Du J, Qian Y, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MT, Blanchard KL, Thomas JE: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-44.
7. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D., Bowtell D, Barretina J, Lin W.M., Rameh L., Salmena L, Pandolfi PP, Cantley LC: Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer cell 2009, 16:115-25.
8. Clark AS, West K, Streicher S., Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Molecular cancer therapeutics 2002, 1:707-17.
9. VanderWeele DJ, Zhou R, Rudin CM: Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Molecular cancer therapeutics 2004, 3:1605-13.
10. Kandel ES, Skeen J, Majewski N., Di Cristofano A, Pandolfi PP, Feliciano C.S., Gartel A., Hay N: Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Molecular and cellular biology 2002, 22:7831-41.
11. Wendel H, de Stanchina E, Fridman JS, Malina A, Ray S., Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428:332-7.
12. Mills JR, Hippo Y, Robert F., Chen Samuel MH, Malina A, Lin C, Trojahn U., Wendel H, Charest A, Bronson R.T., Kogan SC, Nadon R, Housman DE, Lowe SW, Pelletier J: mTORC1 promotes survival through translational control of Mcl-1. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:10853-8.
13. Bozulic L, Surucu B, Hynx D., Hemmings BA: PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Molecular cell 2008, 30:203-13.
14. Liu P, Begley M, Michowski W., Inuzuka H, Ginzberg M, Gao D., Tsou P, Gan W, Papa A., Kim BM, Wan L, Singh A, Zhai B, Yuan M, Wang Z, Gygi SP, Lee TH, Lu K, Toker A, Pandolfi PP, Asara JM, Kirschner MW, Sicinski P, Cantley L, Wei W: Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature 2014, 508:541-5.
15. Wallin JJ, Guan J, Prior W.W., Edgar KA, Kassees R, Sampath D, Belvin M., Friedman LS: Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer. Science translational medicine 2010, 2:48ra66.
16. Hirai H, Sootome H, Nakatsuru Y., Miyama K, Taguchi S, Tsujioka K., Ueno Y, Hatch H, Majumder P.K., Pan B., Kotani H: MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Molecular cancer therapeutics 2010, 9:1956-67.
17. Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL: Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. The Journal of clinical investigation 2010, 120:2406-13.
18. Carver BS, Chapinski C, Wongvipat J., Hieronymus H, Chen Y, Chandarlapaty S., Arora VK, Le C, Koutcher J, Scher H., Scardino PT, Rosen N, Sawyers CL: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer cell 2011, 19:575-86.
19. Baselga J, Campone M, Piccart M., Burris HA, Rugo HS, Sahmoud T, Noguchi S., Gnant M, Pritchard KI, Lebrun F, Beck J.T., Ito Y., Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. The New England journal of medicine 2012, 366:520-9.
20. Mayer IA, Abramson VG, Isakoff S.J., Forero A., Balko JM, Kuba MG, Sanders ME, Yap J.T., Van den Abbeele Annick D, Li Y, Cantley LC, Winer E, Arteaga CL: Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2014, 32:1202-9.
21. Loi S, Haibe-Kains B, Majjaj S., Lallemand F, Durbecq V, Larsimont D., Gonzalez-Angulo AM, Pusztai L, Symmans W.F., Bardelli A., Ellis P, Tutt Andrew NJ, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:10208-13.
22. Ellis MJ, Lin L, Crowder R., Tao Y, Hoog J, Snider J., Davies S, DeSchryver K, Evans D.B., Steinseifer J., Bandaru R, Liu W, Gardner H, Semiglazov V, Watson M, Hunt K, Olson J, Baselga J: Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast cancer research and treatment 2010, 119:379-90.
23. Sabine VS, Crozier C, Brookes C.L., Drake C., Piper T, van de Velde Cornelis JH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea DW, Bartlett John MS: Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2014.
24. Mayer IA, Arteaga CL: PIK3CA Activating Mutations: A Discordant Role in Early Versus Advanced Hormone-Dependent Estrogen Receptor-Positive Breast Cancer? Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2014.
25. Han S, Kim T, Jeon Y.K., Hwang PG, Im S, Lee K, Kim J.H., Kim D., Heo DS, Kim NK, Chung DH, Bang Y: Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clinical cancer research: an official journal of the American Association for Cancer Research 2006, 12:2538-44.
26. Vivanco I, Rohle D, Versele M., Iwanami A, Kuga D, Oldrini B., Tanaka K, Dang J, Kubek S., Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK: The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:6459-64.
27. Berns K, Horlings HM, Hennessy B.T., Madiredjo M., Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M., Beijersbergen RL, Mills GB, van de Vijver Marc J, Bernards R: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer cell 2007, 12:395-402.
28. Stommel JM, Kimmelman AC, Ying H, Nabioullin R., Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner J.E., Ligon KL, Brennan C, Chin L, DePinho RA: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (New York, N.Y.) 2007, 318:287-90.
29. Guix M, Faber AC, Wang S.E., Olivares MG, Song Y, Qu S, Rinehart C., Seidel B, Yee D, Arteaga C.L., Engelman JA: Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. The Journal of clinical investigation 2008, 118:2609-19.
30. Wong MH, Xue A, Julovi S.M., Pavlakis N., Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter R.C., Smith RC: Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2014, 20:4047-58.
31. Saura C, Bendell J, Jerusalem G., Su S, Ru Q, S de Buck, Mills D, Ruquet S, Bosch A, Urruticoechea A, Beck JT, Di Tomaso E, Sternberg DW, Massacesi C, Hirawat S, Dirix L, BaselgaJ: Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clinical cancer research: an official journal of the American Association for Cancer Research 2014, 20:1935-45.
32. Villanueva J, Vultur A, Lee J.T., Somasundaram R., Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X., Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer cell 2010, 18:683-95.
33. Zmajkovicova K, Jesenberger V, Catalanotti F., Baumgartner C, Reyes G, Baccarini M: MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance. Molecular cell 2013, 50:43-55.
34. Engelman JA, Chen L, Tan X., Crosby K, Guimaraes AR, Upadhyay R, Maira M., McNamara K, Perera SA, Song Y, Chirieac L.R., Kaur R., Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong K: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature medicine 2008, 14:1351-6.
35. Posch C, Moslehi H, Feeney L., Green GA, Ebaee A, Feichtenschlager V, Chong K., Peng L, Dimon MT, Phillips T, Daud A.I., McCalmont TH, LeBoit PE, Ortiz-Urda S: Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:4015-20.
36. Lindholm EM, Krohn M, Iadevaia S., Kristian A, Mills GB, Mælandsmo GM, Engebraaten O: Proteomic characterization of breast cancer xenografts identifies early and late bevacizu-mab-induced responses and predicts effective drug combinations. Clinical cancer research: an official journal of the American Association for Cancer Research 2014, 20:404-12.
37. Murillo MM, Zelenay S, Nye E., Castellano E, Lassailly F, Stamp G., Downward J: RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. The Journal of clinical investigation 2014, 124:3601-11.
38. Hähnel PS, Thaler S, Antunes E., Huber C, Theobald M, Schuler M: Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer research 2008, 68:3899-906.
39. Noh KH, Kang TH, Kim J.H., Pai SI, Lin KY, Hung C, Wu T., Kim TW: Activation of Akt as a mechanism for tumor immune evasion. Molecular therapy: the journal of the American Society of Gene Therapy 2009, 17:439-47.
40. Parsa AT, Waldron JS, Panner A, Crane C.A., Parney IF, Barry JJ, Cachola KE, Murray J.C., Tihan T., Jensen MC, Mischel PS, Stokoe D, Pieper RO: Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature medicine 2007, 13:84-8.
41. Song M, Chen D, Lu B., Wang C, Zhang J, Huang L., Wang X, Timmons CL, Hu J, Liu B., Wu X, Wang L, Wang J, Liu H: PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PloS one 2013, 8:e65821.
42. Marshall NA, Galvin KC, Corcoran A.B., Boon L., Higgs R, Mills Kingston HG: Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer research 2012, 72:581-91.
43. Ali K, Soond DR, Piñeiro R, Hagemann T., Pearce W, Lim EL, Bouabe H, Scudamore C.L., Hancox T., Maecker H, Friedman L, Turner M., Okkenhaug K, Vanhaesebroeck B: Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014, 510:407-11.
44. Buonamici S, Williams J, Morrissey M., Wang A, Guo R, Vattay A., Hsiao K, Yuan J, Green J., Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira S, García-Echeverría C, Briggs KJ, Watkins DN, Yao Y, Lengauer C, Warmuth M, Sellers WR, Dorsch M: Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Science translational medicine 2010, 2:51ra70.
45. Dienstmann R, Rodon J, Serra V., Tabernero J: Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Molecular cancer therapeutics 2014, 13:1021-31.
46. Brachmann SM, Kleylein-Sohn J, Gaulis S., Kauffmann A, Blommers Marcel JJ, Kazic-Legueux M, Laborde L, Hattenberger M., Stauffer F, Vaxelaire J, Romanet V, Henry C, Murakami M, Guthy DA, Sterker D, Bergling S, Wilson C, Brümmendorf T, Fritsch C, Garcia-Echeverria C, Sellers WR, Hofmann F, Maira S: Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Molecular cancer therapeutics 2012, 11: 1747-57.
47. Vora SR, Juric D, Kim N., Mino-Kenudson M, Huynh T, Costa C., Lockerman EL, Pollack SF, Liu M, Li X., Lehar J, Wiesmann M, Wartmann M, Chen Y, Cao ZA, Pinzon-Ortiz M, Kim S, Schlegel R, Huang A, Engelman JA: CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer cell 2014, 26:136-49.
48. Elkabets M, Vora S, Juric D., Morse N, Mino-Kenudson M, Muranen T, Tao J., Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S., Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J: mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Science translational medicine 2013, 5:196ra99.
49. Chandarlapaty S, Sawai A, Scaltriti M., Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V., Majumder PK, Baselga J, Rosen N: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell 2011, 19:58-71.
50. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A., Dave B, Cook RS, Pao W, McKinely E., Manning HC, Chang J, Arteaga CL: Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:5021-6.
51. Chakrabarty A, Sánchez V, Kuba M.G., Rinehart C., Arteaga CL: Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:2718-23.
52. O'Reilly KE, Rojo F, She Q., Solit D, Mills GB, Smith D, Lane H., Hofmann F, Hicklin DJ, Ludwig D.L., Baselga J., Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer research 2006, 66:1500-8.
53. Britschgi A, Andraos R, Brinkhaus H., Klebba I, Romanet V, Müller U, Murakami M., Radimerski T, Bentires-Alj M: JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer cell 2012, 22:796-811.
54. Huw L, O'Brien C, Pandita A, Mohan S., Spoerke JM, Lu S, Wang Y, Hampton G.M., Wilson TR, Lackner MR: Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. Oncogenesis 2013, 2:e83.
55. Wagle N, Grabiner BC, Van Allen, Eliezer M, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N., Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA, Lorch JH: Response and acquired resistance to everolimus in anaplastic thyroid cancer. The New England journal of medicine 2014, 371:1426-33.
56. Hassan B, Akcakanat A, Sangai T., Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K., Chen H, Do K, Xie S.M., Holder AM, Naing A, Mills GB, Meric-Bernstam F: Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget 2014, 5:8544-57.
57. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F., Salmena L, Alimonti A, Egia A., Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C., Cantley LC, Baselga J, Pandolfi PP: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. The Journal of clinical investigation 2008, 118:3065-74.
58. Serra V, Scaltriti M, Prudkin L., Eichhorn PJA, Ibrahim YH, Chandarlapaty S, Markman B., Rodriguez O, Guzman M, Rodriguez S., Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J: PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpres-sing breast cancer. Oncogene 2011, 30:2547-57.
59. Serra V, Eichhorn Pieter JA, García-García C, Ibrahim YH, Prudkin L, Sánchez G, Rodríguez O, Antón P, Parra J, Marlow S, Scaltriti M, Pérez-Garcia J, Prat A, Arribas J, Hahn WC, Kim SY, Baselga J: RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. The Journal of clinical investigation 2013, 123:2551-63.
60. Liu P, Cheng H, Santiago S., Raeder M, Zhang F, Isabella A., Yang J, Semaan DJ, Chen C, Fox E.A., Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, Zhao JJ: Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nature medicine 2011, 17:1116-20.
61. Muellner MK, Uras IZ, Gapp B.V., Kerzendorfer C., Smida M, Lechtermann H, Craig-Mueller N, Colinge J., Duernberger G, Nijman Sebastian MB: A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nature chemical biology 2011, 7:787-93.
62. Ilic N, Utermark T, Widlund H.R., Roberts TM: PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:E699-708.
63. Muranen T, Selfors LM, Worster D.T., Iwanicki MP, Song L, Morales FC, Gao S, Mills G.B., Brugge JS: Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer cell 2012, 21:227-39.
64. Juvekar A, Burga LN, Hu H, Lunsford E.P., Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM: Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer discovery 2012, 2:1048-63.
65. González-Billalabeitia E., Seitzer N, Song SJ, Song MS, Patnaik A, Liu X, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP: Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer discovery 2014, 4:896-904.
66. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, BaselgaJ: PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer discovery 2012, 2:1036-47.